178 results about "Ige reactivity" patented technology

The present disclosure provides systems and methods for detecting anti-NMDAR autoantibodies based on the strong affinity of the anti-NMDAR autoantibodies to a plurality of non-random anti-NR1s coupled to a solid support. The present disclosure also provides methods of treatment for anti-NMDAR pathology by the therapeutic anti-NMDAR antibody ART5803. The present disclosure also provides methods and systems for screening and predicting potential responsiveness to ART5803 therapy.

The invention provides antibody conjugate compositions of Formula I comprising an antibody linked by conjugation to one or more target protein binder and VHL ligand (TPI-VHL) moieties. The invention also provides TPI-VHL derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the antibody conjugates through a linker or linking moiety. The invention further provides methods of treating diseases and disorders such as cancer with the antibody conjugates.

The invention provides a single-domain antibody capable of specifically recognizing GPRC5D, which has relatively strong binding activity and reaction specificity, also has good species cross reactivity, is of great significance to research and development in different species models, and is beneficial to acceleration of a transformation process from a laboratory to clinic. The antibody sequences A12 and C07 provided by the invention can be used for constructing chimeric antigen receptor T cells, and the chimeric antigen receptor T cells can be used for treating multiple myeloma.

The disclosure provides the development of enantiomer-specific 7V-arylpyrazole dipeptides as novel N0D2 agonists which are effective at promoting immune checkpoint inhibitor therapy requiring N0D2 for activity. Given the significant functions of N0D2 in innate and adaptive immunity, these novel agonists afford new therapeutic compounds for a variety of NOD2-responsive diseases.

The invention belongs to the field of biology, and discloses an mRNA (messenger ribonucleic acid) with a nucleotide sequence as shown in SEQ ID NO.3. Antiserum of a strain (A / chick / Gansuu / 28 / 2024) corresponding to the mRNA has relatively good reactivity with other strains and poorer reaction with a current vaccine strain RE-13, the branched strain is a current epidemic strain, and the mRNA prepared from the HA gene of the strain has the advantage of strong protection; the invention also aims to provide the mRNA, application thereof and a vaccine.

Provided in the present invention are an anti-TLR7 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition thereof. The antibody or the antigen-binding fragment thereof can specifically bind to a human or simian TLR7 antigen and does not bind to murine TLR7, exhibits significant TLR7 antigen-binding activity, and can effectively inhibit various inflammatory cytokines produced upon TLR7 activation. The anti-TLR7 antibody or the antigen-binding fragment thereof can be used, either as a monotherapy or in combination with other drugs, for treating and / or preventing diseases pathologically associated with the TLR7 target, including immune inflammation-related diseases, allergic diseases, infectious diseases, cancers, etc.

The invention concerns homogenous antibody-conjugates with high payload loading (high DAR) obtained by site-specific conjugation to a single antibody N-glycan. The conjugates according to the invention are homogeneous, i.e. have a DAR at or close to the theoretical DAR with a narrow distribution, and do not require any genetic modification of the antibody. The invention further concerns a modular, non-genetic preparation method for such conjugates, involving three simple steps and starting from any antibody. These steps are (a) enzymatic remodeling of the glycan to give an antibody functionalized with two or four click probes per antibody, (b) strain-promoted cycloaddition with a multivalent, bifunctional reagent comprising one cyclic alkyne and at least two click probes that are not reactive towards the cyclic alkyne, and (c) inverse electron-demand Diels-Alder cycloaddition of the click probes with branched linker-drug constructs comprising one cyclic alkyne or strained alkene, connected to one or more payloads preferably connected through a cleavable linker. The resulting conjugates, with DAR6 or higher, are rapidly generated with high homogeneity and with surprising stability. In addition, HIC profiles of the resulting ADCs indicate small relative retention time and therefore show high potential in the targeting of tumour cells and / or the treatment of cancer.

The invention belongs to the field of biology, and relates to a broad-spectrum monoclonal antibody aiming at avian influenza virus M1 protein and application of the broad-spectrum monoclonal antibody, the monoclonal antibody has specific reaction with A549 cells infected by avian influenza, has no specific reaction with Newcastle disease virus, duck tembusu virus, goose astrovirus and infectious laryngitis virus, has good specificity, and can be used for preparing the broad-spectrum monoclonal antibody. The 5G9 monoclonal antibody has good reactivity with A549 cells infected by H1-H11 subtype AIV, has good broad spectrum, can be used for detecting M1 protein sub-localization after the AIV infected cells are detected by using the 5G9 monoclonal antibody, and can be used for indicating the infection process of the AIV.

The invention provides an anti-TLR7 antibody or an antigen binding fragment and a pharmaceutical composition thereof, the antibody or the antigen binding fragment thereof can be specifically bound with a human or monkey TLR7 antigen and is not bound with mouse TLR7, has remarkable TLR7 antigen binding activity, and can effectively inhibit various inflammatory cytokines generated by TLR7 activation. The anti-TLR7 antibody or the antigen binding fragment thereof can be used as a single agent or a drug combination and can be used for treating and / or preventing diseases related to TLR7 target pathology, including immune inflammation related diseases, allergic diseases, infectious diseases or cancers and the like.

The present invention relates to a biomarker for predicting immunotherapeutic responsiveness based on spatial transcriptome analysis and uses thereof and, in particular, to: a marker composition for predicting the responsiveness of cancer patients to immunotherapy; a composition for predicting the responsiveness of cancer patients to immunotherapy; a kit for predicting the responsiveness of cancer patients to immunotherapy, comprising the composition; a method for providing information for predicting the responsiveness of cancer patients to immunotherapy; and a method for providing information for predicting the survival prognosis of cancer patients. The biomarker for predicting immunotherapeutic responsiveness, according to the present invention, was discovered by applying spatial transcriptome technology and analyzing cell group-specific gene expression values according to location information of cells in tissue sections, and can more precisely and accurately predict the responsiveness of cancer patients to immunotherapy and the survival prognosis of patients, thus enabling suitable treatments for patient groups, which may result in improved therapeutic effects and a reduction in pain and costs for patients.

An assay for autologous primary immune cells is described, in which individual blood cells can be functionally screened simultaneously for individual antigens of interest, such as T-cell epitopes, without the need for HLA haplotype-specific reagents. An oligonucleotide-labeled hash-tracking system, followed by deconvolution via single-cell sequencing, correlates antigen reactivity with individual T cells.

The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more toll-like receptor (TLR), amino-azepine derivatives. The invention also provides TLR agonist amino-azepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

Disclosed are methods of predicting a. subject's responsiveness to an immunotherapy comprising detecting the presence and / or amount of a miR155 gene signature in the subject or a sample from the subject, wherein the miR155 gene signature comprises one or more of miR155, CD3E, CD3G, CD8A, CD8B, CXCR6, FXYD5, GZMB, ID2, IFNgamma, LAGS, NKG7, PDCD1, S100A4, and TIGIT; and comparing the presence and / or amount of the miR155 gene signature to a control sample or threshold, wherein the presence and / or an altered amount of the miR155 gene signature relative to the presence or amount in the control sample or threshold indicates the subject will be responsive or is responding to the immunotherapy.

The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more toll-like receptor (TLR), amino-azepine derivatives. The invention also provides TLR agonist amino-azepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

Providing cancer prediction technology [Solution] This disclosure provides a method for predicting the effectiveness of a cancer vaccine, which includes confirming the reactivity of immune cells (e.g., peripheral blood mononuclear cells) derived from the patient to stimulation by a cancer antigen corresponding to the cancer vaccine or the antigenic portion of the cancer antigen, and predicting and calculating the effectiveness of the cancer vaccine (e.g., response (response and duration) / determining which patients should receive the vaccine) based on the reactivity.

The present invention provides antibody compounds that contain a substitution of cysteine for the reactive lysine residue (lysine 93 by Kabat numbering) in the hydrophobic cleft (38C2_Cys). The invention also provides antibody drug conjugate compounds (ADCs) that contain cargo moieties that are site-specifically conjugated to the engineered cysteine residue in the 38C2_Cys variant antibody. Further provided in the invention are therapeutic applications of the compounds.

The invention provides a fish creatine kinase sensitization and immune cross reactivity analysis method which comprises the following steps: preparing a fish muscle water-soluble protein crude extract, separating 40-45kDa protein components in the fish muscle crude extract through SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis), and screening a target sensitization protein combined with IgE / IgG through immunoblotting; the method comprises the following steps: extracting total RNA of grass carp and synthesizing cDNA, designing a creatine kinase specific primer for amplification to obtain a creatine kinase gene sequence, and carrying out bioinformatics analysis after sequencing verification; the method comprises the following steps: cloning a creatine kinase gene to an expression vector, transforming escherichia coli BL21, performing IPTG induced expression, and performing urea gradient dialysis renaturation on an inclusion body to obtain the recombinant grass carp creatine kinase. Detecting the IgE binding activity of the recombinant grass carp creatine kinase and the serum of the allergic patient through dot hybridization; the IgG cross reactivity of the recombinant grass carp creatine kinase and the blue crab arginine kinase is verified through indirect ELISA; the IgE cross reaction degree of the recombined grass carp creatine kinase and the blue crab arginine kinase is quantified through inhibitory dot hybridization.

Provided are a method of overexpressing a target gene and / or a method of reprogramming cells, the method including steps of (a) introducing a vector into cells, into which vector a promoter and a target gene are inserted; and (b) applying an electromagnetic wave to the cells obtained in the step (a), and a method of treating a disease using the method.When the method of overexpressing a target gene using the electromagnetic wave-reactive promoter of the present disclosure is used, it is possible to artificially regulate expression levels of desired target genes in a simple manner in vivo and in vitro and to regulate expression of the target genes until a desired predetermined time.

The present disclosure relates to antibodies and antibody fragments specific for CCR2. As reactivity with marmoset CCR2, which is a species that is crucial to further preclinical and clinical development, is lost, almost all attempts to humanize the original antibody are notified as failure. The antibodies are useful in the treatment of inflammatory diseases, autoimmune diseases, hematological malignancies, and potentially other diseases.

The disclosure relates to targeted Chromatin Accessibility and Mutation Sequencing (tCAM-seq) for parallel analysis of genetic and epigenetic analysis of patients with pancreatic adenocarcinoma (PDAC) to 1) determine responsiveness to standard of care chemotherapy, and 2) identify actionable allelic variant mutations that can be used to guide treatment decisions. Prognostic methods and treatment strategies are also provided.

Provided herein are recombinant T-cell receptors (TCRs) that can selectively recognize the MAGE-A4-derived peptide GVYDGEEHSV or KVEEHVVRV when presented by HLA-A*0201 sufficiently to activate the recombinant T cell. TCRs provided herein were thoroughly screened for lack of cross-reactivity with similar peptides that may be presented by normal cells or tissue and for alloreactivity.

The invention discloses a multilayer nanofiber oral paste loaded with an allergen-immunologic adjuvant composition as well as a preparation method and application of the multilayer nanofiber oral paste. The multilayer nanofiber oral paste has an adhesion function. The multilayer nanofiber oral paste is prepared by adopting a continuous electrostatic spinning technology, the adhesion layer is prepared from a polymer material, and the backing layer is prepared from a hydrophobic polymer material. The invention relates to an allergen-immunologic adjuvant composition, and the allergen-immunologic adjuvant composition or a composition nanoparticle is loaded by an adhesive layer. The multi-layer nanofiber oral paste is applied to an oral mucosa area of a patient within a treatment course, so that long-acting release of allergens is realized. After the multi-layer nanofiber oral paste is repeatedly used by a patient, the prevention or treatment of allergic diseases (allergic diseases) can be realized.

The invention belongs to the technical field of bioengineering, and particularly relates to a preparation method and application of an N protein polyclonal antibody of a horse coronavirus. The polyclonal antibody is prepared by truncation expression of the horse coronavirus N protein, and a material is provided for research on inhibition of host innate immune mechanism by the horse coronavirus N protein. Prokaryotic expression is carried out on the N protein of the equine coronavirus, the polyclonal antibody is prepared, and a method and a material are provided for molecular research and mechanism research of the equine coronavirus. According to the invention, in combination with bioinformatics analysis of an N protein of the horse coronavirus, a pGEX-6p-N3 recombinant plasmid is constructed, and prokaryotic expression is carried out, so that a purified recombinant protein is obtained. After a mouse is immunized by the recombinant protein, a polyclonal antibody is obtained, an indirect ELISA method detects that the polyclonal antibody has good titer, Western Blot detection has good reactivity, and the polyclonal antibody can be applied to an indirect immunofluorescence test.

The present disclosure provides a method for chemoselective modification of a cell surface molecule on a target cell. A subject method includes contacting a target cell comprising cell surface molecule comprising a thiol, an amine, or an imidazole with a biomolecule comprising a reactive moiety, wherein the reactive moiety is generated by reaction of a biomolecule (e.g., an antibody) comprising a phenol moiety or a catechol with an enzyme capable of oxidizing the phenol or the catechol moiety. The contacting is carried out under conditions sufficient for conjugation of the cell surface molecule to the biomolecule, thereby producing a modified cell. The present disclosure provides kits for carrying out a subject method. The present disclosure also provides modified cells and methods for using same.

Provided herein are compositions, systems, kits, and methods for detecting, in a DNA sample from a subject (e.g., overweight or obese subject), the presence of at least one polymorphism in the Neurobeachin (NBEA) gene. In particular embodiments, once at least one such polymorphism is detected, the subject is treated with, or provided with, a Glucagon-like peptide-1 receptor agonist (GLP-1RA).

The present disclosure provides methods for assessing responsiveness or non-responsiveness to a therapeutic agent (e.g., ICB therapy and / or anti-angiogenic) in subjects having a cancer or tumor based on angio-immune panel signatures. The methods may further comprise identifying suitable treatment for the subject based on the angio-immune panel.

The invention belongs to the technical field of detection, and particularly relates to an anti-swine IgA monoclonal antibody and application thereof in PEDV IgA antibody detection. The invention provides an anti-swine IgA monoclonal antibody and a sequence thereof, the monoclonal antibody is effective to swine IgA, but is ineffective to swine immune globulins IgG, IgM, IgD and IgE, and has good reactivity and specificity. According to the invention, an anti-swine IgA monoclonal antibody is labeled on lanthanide EU3 + fluorescent microspheres, and a time-resolved immunofluorescence test strip detection method is established and is used for qualitative detection of an IgA antibody. The detection method is wide in detection range, high in sensitivity and rapid in detection; good repeatability, accuracy and stability are achieved; in addition, the monoclonal antibody has no cross reaction with porcine immune globulins IgG, IgM, IgD and IgE, is high in specificity, has a clinical detection coincidence rate higher than 97.3%, and has strong clinical application potential.

Some embodiments of the present application provide compounds comprising an Fc-binding unit. These compounds can be used to regiospecifically transfer a group of interest to an antibody. Furthermore, some embodiments of the present application provide methods for preparing antibody conjugates comprising a group of interest (e.g., a reactive group) using these compounds.

The present invention relates to the use of a trispecific antibody that specifically binds to CD19, CD3 and CD28 in the preparation of a drug for treating an autoimmune disease, wherein the autoimmune disease is an autoimmune disease based on a B cell, in particular an autoimmune disease based on an autoreactive B cell.

Described herein are protein-payload conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic and / or imaging agent moieties. In certain embodiments, provided are specific and efficient methods for producing protein-payload constructs (e.g., antibody-drug conjugates) utilizing a combination of transglutaminase and Diels-Alder techniques. Antibody-drug conjugates and compositions which comprise glutaminyl-modified antibodies, Diels-Alder adducts, and reactive payloads and are provided.